Kura Oncology, a biopharmaceutical company specializing in precision cancer medicines, announced it will present at the UBS Global Biopharma London Conference on November 17 and the Jefferies Global Healthcare Conference on November 18, 2026. These presentations provide an opportunity for Kura to update investors on its progress, including its FDA-approved drug KOMZIFTI® for acute myeloid leukemia. Live webcasts will be available on Kura's website, allowing investors to follow the company's latest developments and strategic outlook.
Kura Oncology is the subject of this update, with Pluang providing health sector market context. Of 150 US health stocks on Pluang, 50 rose and 100 fell as of Nov 14, 2026 00:01 WIB. Notable movers include ABEO at USD 2.14 (-6.55%), SANA at USD 1.89 (-6.22%), and OSCR at USD 30.07 (-5.85%).
Susan R. Burns, Ph.D., President of the University of Mount Saint Vincent, has been awarded the 2027 Courageous Leadership Award for her visionary and bold leadership. Since 2021, she has led the university through significant transformation, includi...
Solo, a company specializing in privacy-preserving human verification, has integrated its SDK into JellyJelly, a social video app co-founded by Venmo's co-founder. This integration ensures that every JellyJelly account belongs to a real, unique perso...
The U.S. market for AI-enabled ophthalmic diagnostic devices is projected to grow from $72.5 million in 2026 to $267.2 million by 2033, expanding at a 20.5% CAGR. Growth is driven by rising diabetes-related eye diseases, FDA clearances for autonomous...
The global medical display monitors market, valued at $2.8 billion in 2025, is projected to grow to $4.0 billion by 2033 with a CAGR of 4.6%. Growth is fueled by rising adoption of digital imaging systems, demand for accurate diagnostics, and healthc...
Oppenheimer downgraded Enovix from Outperform to Perform as the company expands production in South Korea and shifts focus to drone and smart-eyewear customers. Enovix reported a 38% revenue increase to $11 million in Q3 but saw its adjusted loss wid...
